GSK pounces on new start-up Aiolos to add anti-TSLP to pipeline

09 Jan 2024
firstwordpharma.com
License out/inAcquisitionDrug Approval
Having emerged from stealth less than three months ago, respiratory medicine developer Aiolos Bio has now snagged a buyout from GSK potentially worth up to $1.4 billion. Meanwhile, the purchase gives GSK the Phase II-ready anti-TSLP monoclonal antibody AIO-001.
“Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio,” remarked Tony Wood, GSK’s chief scientific officer. Amgen and AstraZeneca currently market the anti-TSLP antibody Tezspire (tezepelumab) for patients with severe asthma, with other drugs in the class under development including Sanofi’s SAR443765, a bifunctional compound that also blocks IL-13.
While Tezspire is administered every four weeks, GSK noted that early studies have shown that dosing of AIO-001 can be extended to every six months due to its enhanced potency and prolonged half-life. Beyond asthma, the therapy, which Aiolos licensed from Jiangsu Hengrui Pharmaceuticals in August, also has potential in other indications including chronic rhinosinusitis with nasal polyps.
Under the agreement, GSK will but Aiolos for $1 billion upfront, with the latter eligible for up to $400 million in regulatory milestone payments. In addition, GSK will be responsible for success-based milestone payments as well as tiered royalties owed to Hengrui.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.